MADRIGAL PHARMACEUTICALS, INC. Interest Expense Nonoperating
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Interest Expense Nonoperating of $7.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-06-30 was $7.94M, a 143.26% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2026-03-31 was $7.82M, a 137.15% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-12-31 was $8.30M, a 137.12% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. interest expense nonoperating for the quarter ending 2025-09-30 was $7.45M, a 102.53% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2025 was $22.31M, a 52.06% increase from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2024 was $14.67M, a 15.41% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2023 was $12.71M, a 220.69% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. interest expense nonoperating for fiscal 2022 was $3.96M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.94M 10-Q · filed 2026-07-30 | $15.76M 10-Q · filed 2026-07-30 | $24.06M derived: sum of 3 quarters · filed 2026-07-30 | $31.51M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $7.82M 10-Q · filed 2026-05-06 | $16.12M derived: sum of 2 quarters · filed 2026-05-06 | $23.57M derived: sum of 3 quarters · filed 2026-05-06 | $26.83M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $8.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $15.75M derived: sum of 2 quarters · filed 2026-02-19 | $19.01M derived: sum of 3 quarters · filed 2026-07-30 | $22.31M 10-K · filed 2026-02-19 |
| 2025-09-30 | $7.45M 10-Q · filed 2025-11-04 | $10.71M derived: sum of 2 quarters · filed 2026-07-30 | $14.01M 10-Q · filed 2025-11-04 | $17.51M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $3.26M 10-Q · filed 2026-07-30 | $6.56M 10-Q · filed 2026-07-30 | $10.06M derived: sum of 3 quarters · filed 2026-07-30 | $13.74M derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $3.30M 10-Q · filed 2026-05-06 | $6.80M derived: sum of 2 quarters · filed 2026-05-06 | $10.47M derived: sum of 3 quarters · filed 2026-05-06 | $14.13M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $3.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $7.18M derived: sum of 2 quarters · filed 2026-02-19 | $10.83M derived: sum of 3 quarters · filed 2026-02-19 | $14.67M 10-K · filed 2026-02-19 |
| 2024-09-30 | $3.68M 10-Q · filed 2025-11-04 | $7.33M derived: sum of 2 quarters · filed 2025-11-04 | $11.17M 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $3.66M 10-Q · filed 2025-08-05 | $7.49M 10-Q · filed 2025-08-05 | ||
| 2023-12-31 | $12.71M 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $3.96M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |